PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
February 22, 2026International Journal of Mental Health and Addiction0 citationsOpen Access

Cohort Profile: The Austrian National Opioid Agonist Treatment Cohort (OAT-AT)

TSTanja SchwarzMBMartin BuschMBMartin Busch

Key Points

  • The study aims to analyze factors influencing treatment retention and mortality outcomes in opioid agonist treatment participants.
  • Utilized a national open-ended OAT registry for data collection.
  • Linked cohort data with national death registry for mortality analysis.
  • Included data from all participants recorded from 2002 to 2019.
  • Analyzed numerous episodes of treatment and follow-up durations.
  • Involves 26,031 individuals with 39,024 OAT episodes.
  • Median episode duration was 914 days and mean duration 1,716 days.
  • Total follow-up time amounted to 278,959 person-years, with 66% within OAT.
  • 76% of participants were male, with a median age of 26 at cohort entry.

Abstract

Abstract The Austrian National Opioid Agonist Treatment (OAT-AT) cohort comprises all participants recorded in the pseudonymised statistical sub-registry of the national, open-ended OAT registry since its initiation in January 1, 2002 through December 31, 2019. Data linkage with the Austrian national death registry took place until December 31, 2021. Whereas the OAT registry primarily serves administrative monitoring, OAT-AT links its statistical sub-registry with mortality data to investigate the factors influencing treatment retention and outcomes, as well as mortality rates and causes of death. The cohort includes 26,031 individuals, representing 39,024 OAT episodes (i.e. distinct periods, defined by start and end date during which an individual is authorized by a prescribing physician to receive OAT) with a median episode duration of 914 days and a mean of 1,716 days. The total follow-up time was 278 959 person-years (PY) as of December 31, 2021, with 183 289 PY during OAT (66%) and 95 671 PY (34%) outside of OAT. Median age at cohort entry was 26 years and 76% were male. Findings from OAT-AT will provide new insights into mortality risk and the patient, treatment, and provider factors influencing treatment retention and long-term mortality trends. These findings will facilitate the development of strategies designed to optimize OAT modalities, improve treatment retention, and expand diverse treatment models to enhance access and effectiveness for individuals receiving OAT.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Schwarz et al. (2026) studied this question.

synapsesocial.com/papers/699a9d8e482488d673cd3838https://doi.org/10.1007/s11469-026-01639-x
Ask AI
Helpful
Bookmark
Share
View Full Paper